Ana Sayfa
Piyasalar
Grafikler ve Fikirler
Algo
Haberler
Store
Aracı Kurumlar
İndir
Ekonomik Takvim
Alım-Satım Sinyalleri
Web Terminali
Heatmap
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
PRLD
#3373
Prelude Therapeutics Incorporated
5.0
6
USD
+15.00%
Sektör:
Sağlık Hizmetleri
Baz:
USD
Kar Para Birimi:
USD
Günlük Aralık
Yıllık Aralık
Günlük Değişim
+15.00%
Aylık Değişim
+51.04%
6 aylık değişim
+272.06%
Yıllık Değişim
+565.79%
Önceki Kapanış
4.4
0
Open
4.8
1
Bid
Ask
Low
4.8
1
High
5.0
6
Hacim
116
Piyasalar
ABD Borsası
Sağlık Hizmetleri
PRLD
Open full chart
Financials
Overview
Rapor
Statistics
Quarterly
Annual
Value
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
42.3 M
43.6 M
43.74 M
43.75 M
48.23 M
179.32 M
Valuation ratios
Enterprise value
57.85 M
3.09 M
20.06 M
42.99 M
147.45 M
213.6 M
Price to earnings ratio
-0.76
-0.46
-0.5
-0.99
-2.25
-4.19
Price to sales ratio
13.81
—
—
—
18.38
—
Price to cash flow ratio
-0.94
-0.55
-0.57
-1.09
-3.96
-6.18
Price to book ratio
0.74
0.1
0.13
0.3
3.25
3.78
Enterprise value to EBITDA ratio
-0.42
—
—
—
-1.43
—
Profitability ratios
Return on assets %
-0.16
-0.23
-0.27
-0.21
-0.12
-0.82
Return on equity %
-0.22
-0.31
-0.41
-0.34
-0.24
-1.3
Return on invested capital %
—
—
—
—
-124.75
—
Gross margin %
100
—
—
100
100
—
Operating margin %
-845.78
—
—
-314.12
-307.59
—
EBITDA margin %
-833.55
—
—
-307.58
-300.18
—
Net margin %
-718.28
—
—
-303.46
-291.79
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
5.3
5.18
3.68
3.21
1.99
14.05
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.02
—
—
0.06
0.05
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.27
-0.45
-0.34
-0.25
0.3
-0.74
EBIT per share
-0.45
—
—
-0.27
-0.23
—
EBITDA per share
-0.44
—
—
-0.26
-0.22
—
Total debt per share
—
—
—
—
—
—
Cash per share
1.76
1.3
0.96
0.72
1.34
4.33
Net current asset value per share
1.79
1.35
1.01
0.77
1.37
4.5
Tangible book value per share
1.73
1.36
1
0.77
0.89
4.02
Working capital per share
1.45
1.09
0.74
0.53
0.68
3.04
Book value per share
1.73
1.36
1
0.77
0.89
4.02
Haberler
Prelude Therapeutics, Jefferies aracılığıyla 25 milyon dolarlık hisse satışı için başvurdu
Prelude Therapeutics files to offer up to $25 million in stock through Jefferies
Citizens, JAK2 potansiyeli nedeniyle Prelude hedefini yükseltti
Citizens raises Prelude Therapeutics price target on JAK2 potential
Prelude Therapeutics hissesi Citizens’tan "Piyasa Performansının Üzerinde" notu aldı
Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens
Prelude Therapeutics hisseleri kanser ilacı için FDA onayı sonrası yükseldi
Prelude Therapeutics stock surges after FDA clears IND for cancer drug
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Mizuho, ASH’deki umut verici veriler sonrası Incyte hisse senedi notunu Outperform’a yükseltti
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus